Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging-Guided Co-Delivery of siRNA and Doxorubicin
- PDF / 1,482,499 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 32 Downloads / 184 Views
ARTICLE
Cite as Nano-Micro Lett. (2019) 11:27 Received: 24 January 2019 Accepted: 6 March 2019 © The Author(s) 2019
https://doi.org/10.1007/s40820-019-0257-1
Photostable and Biocompatible Fluorescent Silicon Nanoparticles for Imaging‑Guided Co‑Delivery of siRNA and Doxorubicin to Drug‑Resistant Cancer Cells Daoxia Guo1, Xiaoyuan Ji1, Fei Peng1, Yiling Zhong1, Binbin Chu1, Yuanyuan Su1 *, Yao He1 * Daoxia Guo and Xiaoyuan Ji contributed equally to this work. * Yuanyuan Su, [email protected]; Yao He, [email protected] Laboratory of Nanoscale Biochemical Analysis, Jiangsu Key Laboratory for Carbon‑Based Functional Materials and Devices, Institute of Functional Nano and Soft Materials (FUNSOM), Soochow University, Suzhou 215123, Jiangsu, People’s Republic of China
1
HIGHLIGHTS • A novel all-in-one fluorescent nanomedicine platform based on silicon nanoparticles (SiNPs) was developed for imaging-guided codelivery of short interfering RNA (siRNA) and doxorubicin (DOX). • The intracellular time-dependent release behaviors of siRNA and DOX were visually monitored by tracking the strong and stable fluorescence of SiNPs. • The SiNPs-based nanocarriers displayed pronounced therapeutic efficiency on drug-resistant breast cancer cells.
ABSTRACT The development of effective and safe vehicles to deliver small interfering RNA (siRNA) and chemotherapeutics remains a major challenge in
RNA interference-based combination therapy with chemotherapeutics, which has emerged as a powerful platform to treat drug-resistant cancer cells. Herein, we describe the development of novel all-in-one fluorescent silicon nanoparti‑ cles (SiNPs)-based nanomedicine platform for imaging-guided co-delivery of siRNA and doxorubicin (DOX). This approach enhanced therapeutic efficacy in multidrug-resistant breast cancer cells (i.e., MCF-7/ADR cells). Typically, the SiNP-based nanocarriers enhanced the stability of siRNA in a biological environ‑ ment (i.e., medium or RNase A) and imparted the responsive release behavior of siRNA, resulting in approximately 80% down-regulation of P-glycoprotein expression. Co-delivery of P-glycoprotein siRNA and DOX led to > 35-fold decrease in the half maximal inhibitory concentration of DOX in comparison with free DOX, indicating the pronounced therapeutic efficiency of the resultant nanocomposites for drug-resistant breast cancer cells. The intracellular time-dependent release behaviors of siRNA and DOX were revealed through tracking the strong and stable fluorescence of SiNPs. These data provide valuable information for designing effective RNA interference-based co-delivery carriers. KEYWORDS Fluorescent silicon nanoparticles; Drug resistance; Gene therapy; Bioimaging Vol.:(0123456789)
13
27
Page 2 of 13
1 Introduction Despite great progress in cancer treatment, multidrug resist‑ ance (MDR), which can lead to high recurrence rates and treatment failures, remains a tremendous challenge in cancer chemotherapy [1]. Generally, the abnormal expression of related genes on drug efflux, metabolism and targets
Data Loading...
